Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 10 | 2022 | 205 | 1.970 |
Why?
|
| Genital Neoplasms, Female | 5 | 2021 | 108 | 1.800 |
Why?
|
| Oncologists | 3 | 2021 | 36 | 1.640 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 1363 | 0.950 |
Why?
|
| Ovarian Neoplasms | 5 | 2022 | 763 | 0.920 |
Why?
|
| Intestinal Obstruction | 2 | 2021 | 88 | 0.890 |
Why?
|
| Drug Costs | 1 | 2021 | 63 | 0.730 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 461 | 0.630 |
Why?
|
| Telemedicine | 1 | 2021 | 185 | 0.630 |
Why?
|
| Adenocarcinoma | 3 | 2015 | 1194 | 0.470 |
Why?
|
| Pandemics | 5 | 2022 | 771 | 0.440 |
Why?
|
| Carcinosarcoma | 1 | 2011 | 21 | 0.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2552 | 0.370 |
Why?
|
| Uterine Neoplasms | 2 | 2019 | 245 | 0.330 |
Why?
|
| Endometrial Hyperplasia | 2 | 2022 | 11 | 0.330 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2022 | 49 | 0.330 |
Why?
|
| Female | 25 | 2022 | 46011 | 0.330 |
Why?
|
| Palliative Care | 2 | 2021 | 263 | 0.320 |
Why?
|
| Humans | 28 | 2022 | 89063 | 0.260 |
Why?
|
| Carcinoma, Papillary | 1 | 2007 | 159 | 0.260 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 1706 | 0.260 |
Why?
|
| Colorectal Neoplasms | 2 | 2021 | 981 | 0.220 |
Why?
|
| Quality of Life | 2 | 2022 | 1662 | 0.220 |
Why?
|
| Mental Health | 2 | 2021 | 176 | 0.220 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 582 | 0.200 |
Why?
|
| Aged | 13 | 2022 | 19077 | 0.200 |
Why?
|
| Morbidity | 1 | 2022 | 149 | 0.200 |
Why?
|
| Decision Trees | 1 | 2021 | 59 | 0.190 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 45 | 0.190 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 49 | 0.190 |
Why?
|
| Hysterectomy | 3 | 2019 | 151 | 0.190 |
Why?
|
| Markov Chains | 1 | 2021 | 127 | 0.190 |
Why?
|
| Papillomavirus Vaccines | 1 | 2021 | 58 | 0.190 |
Why?
|
| Quinolines | 1 | 2021 | 91 | 0.180 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 114 | 0.180 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 142 | 0.180 |
Why?
|
| Hyperthermia, Induced | 1 | 2021 | 73 | 0.180 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 2001 | 0.180 |
Why?
|
| Chicago | 3 | 2020 | 1423 | 0.180 |
Why?
|
| Depression | 2 | 2021 | 503 | 0.180 |
Why?
|
| Carboplatin | 1 | 2021 | 304 | 0.180 |
Why?
|
| Peritoneal Neoplasms | 1 | 2021 | 184 | 0.170 |
Why?
|
| Referral and Consultation | 2 | 2020 | 341 | 0.170 |
Why?
|
| Paclitaxel | 1 | 2021 | 479 | 0.170 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1067 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 261 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 967 | 0.150 |
Why?
|
| Health Resources | 1 | 2018 | 81 | 0.150 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 6777 | 0.150 |
Why?
|
| Stress, Psychological | 1 | 2021 | 321 | 0.150 |
Why?
|
| Health Equity | 1 | 2020 | 94 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 373 | 0.150 |
Why?
|
| Communication | 1 | 2021 | 457 | 0.150 |
Why?
|
| Self Care | 1 | 2018 | 164 | 0.150 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 92 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 625 | 0.130 |
Why?
|
| Middle Aged | 13 | 2021 | 25863 | 0.130 |
Why?
|
| Corneal Injuries | 1 | 2015 | 10 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 296 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 410 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.120 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 159 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 485 | 0.120 |
Why?
|
| Retrospective Studies | 8 | 2021 | 9003 | 0.110 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 170 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 376 | 0.110 |
Why?
|
| Obesity | 1 | 2018 | 966 | 0.100 |
Why?
|
| Sexual Behavior | 1 | 2015 | 309 | 0.100 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 1108 | 0.100 |
Why?
|
| Adult | 10 | 2021 | 26507 | 0.100 |
Why?
|
| Prostatectomy | 1 | 2015 | 476 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2012 | 150 | 0.100 |
Why?
|
| Prognosis | 3 | 2021 | 3773 | 0.090 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2021 | 76 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 309 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2012 | 372 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 295 | 0.080 |
Why?
|
| Anxiety | 2 | 2021 | 308 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 285 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 988 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 616 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2017 | 2275 | 0.080 |
Why?
|
| Young Adult | 5 | 2021 | 6288 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1543 | 0.070 |
Why?
|
| Disease-Free Survival | 3 | 2015 | 1214 | 0.070 |
Why?
|
| Neoplasms | 1 | 2021 | 3035 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 2411 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 1096 | 0.060 |
Why?
|
| Adolescent | 3 | 2021 | 9237 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 848 | 0.060 |
Why?
|
| Incidence | 2 | 2021 | 1592 | 0.060 |
Why?
|
| United States | 3 | 2021 | 6955 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2022 | 1855 | 0.060 |
Why?
|
| Risk Factors | 3 | 2021 | 5466 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2007 | 1533 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 2863 | 0.050 |
Why?
|
| Age Factors | 1 | 2007 | 1867 | 0.050 |
Why?
|
| Rural Health Services | 1 | 2021 | 17 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2021 | 8203 | 0.050 |
Why?
|
| Rural Population | 1 | 2021 | 143 | 0.050 |
Why?
|
| Geography | 1 | 2021 | 227 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 859 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 233 | 0.040 |
Why?
|
| Social Class | 1 | 2020 | 135 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 131 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2019 | 17 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 273 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 220 | 0.040 |
Why?
|
| Urban Population | 1 | 2018 | 224 | 0.040 |
Why?
|
| Poverty | 1 | 2018 | 180 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2018 | 95 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 531 | 0.030 |
Why?
|
| Endometrium | 1 | 2015 | 50 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 66 | 0.030 |
Why?
|
| Sexuality | 1 | 2015 | 41 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2015 | 174 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 216 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 372 | 0.030 |
Why?
|
| Self Report | 1 | 2015 | 295 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 393 | 0.030 |
Why?
|
| Robotics | 1 | 2015 | 269 | 0.020 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 304 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2012 | 225 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2012 | 121 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1212 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 682 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1591 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2335 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 364 | 0.020 |
Why?
|
| Child | 1 | 2021 | 7149 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1650 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2015 | 771 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1768 | 0.010 |
Why?
|
| Time Factors | 1 | 2012 | 5320 | 0.010 |
Why?
|
| Male | 1 | 2015 | 42251 | 0.010 |
Why?
|